Mefenorex (Rondimen, Pondinil, Anexate) is a stimulant drug which was used as an appetite suppressant. It is an amphetamine derivative which was developed in the 1970s and used for the treatment of obesity.[2][3] Mefenorex produces amphetamine as a metabolite,[4] and has been withdrawn in many countries despite having only mild stimulant effects and relatively little abuse potential.[5]

Mefenorex
Clinical data
Trade namesRondimen, Pondinil, Anexate
ATC code
Legal status
Legal status
Identifiers
  • 3-chloro-N-(1-methyl-2-phenylethyl)propan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.037.511 Edit this at Wikidata
Chemical and physical data
FormulaC12H18ClN
Molar mass211.73 g·mol−1
3D model (JSmol)
  • ClCCCNC(Cc1ccccc1)C
  • InChI=1S/C12H18ClN/c1-11(14-9-5-8-13)10-12-6-3-2-4-7-12/h2-4,6-7,11,14H,5,8-10H2,1H3 checkY
  • Key:XXVROGAVTTXONC-UHFFFAOYSA-N checkY
  (verify)

References

edit
  1. ^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  2. ^ Vincendeau MJ (1970). "[A new regulator of appetite: mefenorex]". Bordeaux Medical (in French). 3 (7): 1951–3. PMID 5455004.1951-3&rft.date=1970&rft_id=info:pmid/5455004&rft.aulast=Vincendeau&rft.aufirst=MJ&rfr_id=info:sid/en.wikipedia.org:Mefenorex" class="Z3988">
  3. ^ Beyer G, Huth K, Müller GM, Niemöller H, Raisp I, Vorberg G (February 1980). "[The treatment of obesity with the appetite curbing agent Mefenorex]". Die Medizinische Welt (in German). 31 (8): 306–9. PMID 7374423.306-9&rft.date=1980-02&rft_id=info:pmid/7374423&rft.aulast=Beyer&rft.aufirst=G&rft.au=Huth, K&rft.au=Müller, GM&rft.au=Niemöller, H&rft.au=Raisp, I&rft.au=Vorberg, G&rfr_id=info:sid/en.wikipedia.org:Mefenorex" class="Z3988">
  4. ^ Rendić S, Slavica M, Medić-Sarić M (1994). "Urinary excretion and metabolism of orally administered mefenorex". European Journal of Drug Metabolism and Pharmacokinetics. 19 (2): 107–17. doi:10.1007/BF03188831. PMID 8001591. S2CID 7170057.107-17&rft.date=1994&rft_id=https://api.semanticscholar.org/CorpusID:7170057#id-name=S2CID&rft_id=info:pmid/8001591&rft_id=info:doi/10.1007/BF03188831&rft.aulast=Rendić&rft.aufirst=S&rft.au=Slavica, M&rft.au=Medić-Sarić, M&rfr_id=info:sid/en.wikipedia.org:Mefenorex" class="Z3988">
  5. ^ Engel J, Kristen G, Schaefer A, von Schlichtegroll A (June 1986). "Mefenorex (Rondimen)". Drug and Alcohol Dependence. 17 (2–3): 229–34. doi:10.1016/0376-8716(86)90010-4. PMID 3743406.2–3&rft.pages=229-34&rft.date=1986-06&rft_id=info:doi/10.1016/0376-8716(86)90010-4&rft_id=info:pmid/3743406&rft.aulast=Engel&rft.aufirst=J&rft.au=Kristen, G&rft.au=Schaefer, A&rft.au=von Schlichtegroll, A&rfr_id=info:sid/en.wikipedia.org:Mefenorex" class="Z3988">